Skip to main content
Premium Trial:

Request an Annual Quote

IBM and Accelrys in Four-Year Drug Discovery IT Alliance

 

NEW YORK, Jan. 7—IBM and Pharmacopeia subsidiary Accelrys have formed a wide-ranging drug discovery hardware and software technology and marketing alliance, the two firms said Monday.

 

The partnership, slated to last four years, will pair Accelrys' drug discovery software with IBM's server technology.

 

As part of the agreement, IBM also becomes Accelrys' preferred technology partner for life sciences, and its eServer systems will be the company's standard server. The software firm will use the IBM Regatta p690 system, the xSeries systems for Linux and Windows NT and the eServer Cluster 1300 system for Linux.

 

The two companies will jointly market drug discovery computer technology, including Accelrys' planned Discovery Studio platform, intended to integrate the entire process of drug discovery and development. IBM's DiscoveryLink data integration technology will be part of this new platform.

 

Accelrys will also enable its drug discovery applications to run optimally on eServer systems.

 

Accelrys also becomes a "premier partner" in IBM's "PartnerWorld for Developers Program," giving it top-drawer status as an IBM partner and access to the computer giant's sales, education, training and technical support programs.

 

The alliance is "one of the most significant and influential relationships for IBM in life sciences," said IBM Life Sciences general manager Caroline Kovac in a statement.

 

Accelrys was formed from Pharmacopeia's software subsidiaries last April. It is based in San Diego and Cambridge, UK.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.